Published on 28/12/2025
Managing Tablet Core Erosion in Enteric-Coated Tablets
Introduction:
Enteric-coated tablets represent a sophisticated drug delivery system designed to bypass the acidic environment of the stomach and to release their active ingredients in the more neutral pH of the intestines. This method of delivery is essential for drugs that are inactivated by gastric acids or those that can irritate the gastric mucosa. However, ensuring the integrity of the enteric coat until it reaches the intestines is a significant challenge in pharmaceutical formulation. Tablet core erosion—a phenomenon where the core of the tablet begins to degrade before reaching the target site—can compromise the efficacy of the drug, leading to suboptimal therapeutic outcomes. This article delves into the challenges of tablet core erosion in enteric-coated tablets and provides a comprehensive troubleshooting guide and regulatory insights to effectively manage this issue.
Challenges and Issues:
- Inadequate coating adhesion leading to premature dissolution in the stomach.
- Variability in coating thickness and uniformity affecting drug release profiles.
- Formulation-specific issues such as hygroscopicity, which can impact the stability of the core.
- Environmental factors like humidity and temperature during storage affecting the integrity of the coating.
- Manufacturing process variations causing differences in tablet core hardness and porosity.
Step-by-Step Troubleshooting Guide:
- Evaluate
Regulatory Guidelines:
The development and manufacture of enteric-coated tablets are guided by stringent regulatory standards to ensure safety and efficacy. The USFDA provides comprehensive guidelines on the expected performance of delayed-release oral dosage forms. These include recommendations for in vitro dissolution testing to simulate gastrointestinal conditions, as well as stability testing protocols. Adhering to these guidelines helps ensure that the enteric coating performs as intended, releasing the active ingredient only at the target site in the intestines.
Conclusion:
Managing tablet core erosion in enteric-coated tablets requires a multifaceted approach that includes careful selection of materials, optimization of manufacturing processes, and adherence to regulatory guidelines. By addressing the challenges of coating adhesion, environmental stability, and formulation compatibility, pharmaceutical professionals can enhance the efficacy of enteric-coated tablets. Implementing robust quality control measures and leveraging modern formulation technologies will further ensure that these advanced drug delivery systems meet their therapeutic objectives effectively.